A Belatacept Compassionate Use Study for Patients With a Kidney Transplant
Belatacept for Renal Allograft Recipients: A Compassionate Use Program
Sponsor: Bristol-Myers Squibb
Listed as NCT00719225, this observational or N/A phase trial focuses on Renal Transplantation and remains ongoing. Sponsored by Bristol-Myers Squibb, it has been updated 8 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Dec 2021 — Jul 2024 [monthly]
No Longer Available
Status: Approved For Marketing → No Longer Available
-
Jan 2021 — Dec 2021 [monthly]
Approved For Marketing
-
Jun 2018 — Jan 2021 [monthly]
Approved For Marketing
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Approved For Marketing
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Approved For Marketing NA
-
Jan 2017 — Feb 2017 [monthly]
Approved For Marketing NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .